Thousands of cancer patients could qualify for ‘effective and valuable’ treatment
NHS gets new prostate drug: Thousands of cancer patients could qualify for ‘effective and valuable’ treatment after green-light from health watchdog
- Thousands of prostate cancer patients will be eligible for an ‘effective’ treatment
- Some 8,000 people in England will be eligible for treatment with apalutamide
- A health watchdog recommended it for people with hormone-relapsed cancer
- It comes as a discount was agreed for the drug to be made available on the NHS
<!–
<!–
<!–
<!–
<!–
(function (src, d, tag){
var s = d.createElement(tag), prev = d.getElementsByTagName(tag)[0];
s.src = src;
prev.parentNode.insertBefore(s, prev);
}(“https://www.dailymail.co.uk/static/gunther/1.17.0/async_bundle–.js”, document, “script”));
<!–
DM.loadCSS(“https://www.dailymail.co.uk/static/gunther/gunther-2159/video_bundle–.css”);
<!–
Thousands of cancer patients will be eligible for an ‘effective and valuable’ treatment after it was recommended by a health watchdog.
Some 8,000 people in England with hormone-sensitive or hormone-relapsed prostate cancer will be eligible for treatment with apalutamide.
It comes after a discount was agreed for the drug, also called Erleada and made by pharmaceutical giant Janssen, to be available on the NHS.
A pack of 112 tablets normally costs £2,735, but a confidential discount has been agreed, the National Institute for Health and Care Excellence (Nice) said.
Some 8,000 people in England with hormone-relapsed prostate cancer will be eligible for treatment with apalutamide after it was recommended by a health watchdog (stock image)
Apalutamide blocks the effect of testosterone on prostate cancer cells.
Nice has recommended it for those with hormone-relapsed prostate cancer at high risk of spreading, and for certain people with hormone-sensitive metastatic prostate cancer.
Around 48,000 people are diagnosed with prostate cancer a year in the UK.
- We need even MORE cash, NHS bosses tell Boris: Chiefs demand… Heartbreak as one-year-old girl battles cancer just months…
Meindert Boysen, Nice deputy chief executive and director of the centre for health technology evaluation, said: ‘We are very pleased that Janssen has been able to work with us to address the uncertainties in the evidence identified by the committee in the previous draft guidance.
‘This means that we are able to produce final draft guidance recommending apalutamide as an effective and valuable additional treatment option for people with these types of prostate cancer.’
Comments 12
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Close
Do you want to automatically post your MailOnline comments to your Facebook Timeline?
Your comment will be posted to MailOnline as usual.
Close
Do you want to automatically post your MailOnline comments to your Facebook Timeline?
Your comment will be posted to MailOnline as usual
We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account. We’ll ask you to confirm this for your first post to Facebook.
You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy.